Clinical Trial Update: LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

View source ↗

Summary

Clinical trial update indicating the post-marketing surveillance study of LYNPARZA for adjuvant breast cancer in Japan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Status: COMPLETED